- Home
- ATXI vs NBY Comparison
ATXI vs NBY Comparison
Compare ATXI & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXI
- NBY
- Stock Information
- Founded
- ATXI 2015
- NBY 2000
- Country
- ATXI United States
- NBY United States
- Employees
- ATXI N/A
- NBY N/A
- Industry
- ATXI Biotechnology: Pharmaceutical Preparations
- NBY
- Sector
- ATXI Health Care
- NBY
- Exchange
- ATXI Nasdaq
- NBY Nasdaq
- Market Cap
- ATXI 3.0M
- NBY 3.3M
- IPO Year
- ATXI 2017
- NBY 2007
- Fundamental
- Price
- ATXI $1.85
- NBY $0.53
- Analyst Decision
- ATXI
- NBY Strong Buy
- Analyst Count
- ATXI 0
- NBY 1
- Target Price
- ATXI N/A
- NBY $0.85
- AVG Volume (30 Days)
- ATXI 22.1K
- NBY 77.8K
- Earning Date
- ATXI 11-14-2024
- NBY 11-07-2024
- Dividend Yield
- ATXI N/A
- NBY N/A
- EPS Growth
- ATXI N/A
- NBY N/A
- EPS
- ATXI N/A
- NBY N/A
- Revenue
- ATXI N/A
- NBY $13,844,000.00
- Revenue This Year
- ATXI N/A
- NBY N/A
- Revenue Next Year
- ATXI N/A
- NBY $26.04
- P/E Ratio
- ATXI N/A
- NBY N/A
- Revenue Growth
- ATXI N/A
- NBY 15.40
- 52 Week Low
- ATXI $1.60
- NBY $0.36
- 52 Week High
- ATXI $26.48
- NBY $10.15
- Technical
- Relative Strength Index (RSI)
- ATXI 30.21
- NBY 35.25
- Support Level
- ATXI $1.80
- NBY $0.52
- Resistance Level
- ATXI $1.88
- NBY $0.58
- Average True Range (ATR)
- ATXI 0.11
- NBY 0.03
- MACD
- ATXI -0.02
- NBY -0.00
- Stochastic Oscillator
- ATXI 0.00
- NBY 11.56
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.